Abstract
HGF is a mesenchyme-derived pleiotropic factor, which regulates cell growth, cell motility, and morphogenesis of various types of cells and is thus considered a humoral mediator of epithelial-mesenchymal interactions responsible for morphogenic tissue interactions during embryonic development and organogenesis. Although HGF was originally identified as a potent mitogen for hepatocytes, it has also been identified as a member of angiogenic growth factors. Interestingly, the presence of its specific receptor, c-met, is observed in vascular cells and cardiac myocytes. In addition, among growth factors, the mitogenic action of HGF on human endothelial cells was most potent. Recent studies have demonstrated the potential application of HGF to treat cardiovascular diseases such as peripheral vascular disease, myocardial infarction and cerebrovascular disease. In this review, we will discuss a potential therapeutic strategy using HGF in cardiovascular disease.
Keywords: angiogenesis, restenosis, gene therapy, peripheral vascular disease, myocardial infarction
Current Gene Therapy
Title: Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Volume: 4 Issue: 2
Author(s): Ryuichi Morishita, Motokuni Aoki, Naotaka Hashiya, Keita Yamasaki, Hitomi Kurinami, Shiro Shimizu, Hirofumi Makino, Yasushi Takesya, Junya Azuma and Toshio Ogihara
Affiliation:
Keywords: angiogenesis, restenosis, gene therapy, peripheral vascular disease, myocardial infarction
Abstract: HGF is a mesenchyme-derived pleiotropic factor, which regulates cell growth, cell motility, and morphogenesis of various types of cells and is thus considered a humoral mediator of epithelial-mesenchymal interactions responsible for morphogenic tissue interactions during embryonic development and organogenesis. Although HGF was originally identified as a potent mitogen for hepatocytes, it has also been identified as a member of angiogenic growth factors. Interestingly, the presence of its specific receptor, c-met, is observed in vascular cells and cardiac myocytes. In addition, among growth factors, the mitogenic action of HGF on human endothelial cells was most potent. Recent studies have demonstrated the potential application of HGF to treat cardiovascular diseases such as peripheral vascular disease, myocardial infarction and cerebrovascular disease. In this review, we will discuss a potential therapeutic strategy using HGF in cardiovascular disease.
Export Options
About this article
Cite this article as:
Morishita Ryuichi, Aoki Motokuni, Hashiya Naotaka, Yamasaki Keita, Kurinami Hitomi, Shimizu Shiro, Makino Hirofumi, Takesya Yasushi, Azuma Junya and Ogihara Toshio, Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF), Current Gene Therapy 2004; 4 (2) . https://dx.doi.org/10.2174/1566523043346453
DOI https://dx.doi.org/10.2174/1566523043346453 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension
Current Vascular Pharmacology HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design Nanoparticulate Iron Oxide Contrast Agents for Untargeted and Targeted Cardiovascular Magnetic Resonance Imaging
Current Nanoscience Acute Severe Arterial Hypertension: Therapeutic Options
Current Drug Targets Phytochemicals and Antioxidants: An Evaluation in Understanding the Human Lifeline
Current Nutrition & Food Science Nano-biotechnology and its Innovative Perspective in Diabetes Management
Mini-Reviews in Medicinal Chemistry The Classic Basic Protein of Myelin – Conserved Structural Motifs and the Dynamic Molecular Barcode Involved in Membrane Adhesion and Protein-Protein Interactions
Current Protein & Peptide Science Role of Endothelial Nitric Oxide in Cerebrovascular Regulation
Current Pharmaceutical Biotechnology Second-Generation Antipsychotic Agents: A Review of Safety Profiles
Current Psychiatry Reviews Protein Kinase C – Possible Therapeutic Target to Treat Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Age-Related Sleep Changes and its Implication in Neurodegenerative Diseases
Current Aging Science Gene Therapy (Part II)
Current Gene Therapy Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Current Vascular Pharmacology Therapeutic Modulation of Coagulation and Fibrinolysis in Acute Lung Injury and the Acute Respiratory Distress Syndrome
Current Pharmaceutical Biotechnology Systems Biology and Biomechanical Model of Heart Failure
Current Cardiology Reviews Adiponectin: A Key Player in Obesity Related Disorders
Current Pharmaceutical Design Microbial Biotransformation: Recent Developments on Steroid Drugs
Recent Patents on Biotechnology Pros and Cons of Aggressive Blood Pressure Lowering in Patients with Type 2 Diabetes
Current Vascular Pharmacology Cardiovascular Disease Risk Among the Poor and Homeless – What We Know So Far
Current Cardiology Reviews Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews